The Latest Lung Cancer Journal Articles

Keep up to date with the latest in lung cancer. Check out the latest lung cancer articles from leading medical journals in a single view, helping you discover relevant articles quickly and easily

• Predicting Lymph Node Metastasis in Non-Small Cell Lung Cancer: Prospective External and Temporal Validation of the HAL and HOMER Models.1st May 2021
  Two models, the Help with the Assessment of Adenopathy in Lung cancer (HAL) and Help with Oncologic Mediastinal Evaluation for Radiation (HOMER), were recently developed to estimate the probability of nodal disease in non-small cell lung cancer (NSCLC) patients as determined by endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA). The objective of this study was to prospectively […]
• Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: Protocol-Specified Final Analysis From KEYNOTE-189.24th April 2021
  In the phase 3 KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with previously untreated metastatic nonsquamous NSCLC versus placebo plus pemetrexed-platinum. We report updated efficacy outcomes from the protocol-specified final analysis, including outcomes in patients who crossed over to pembrolizumab from […]
• Molecular Biomarker and Program Death-Ligand 1 Expression Testing in Patients with Advanced Stage Non-Small Cell Lung Cancer Across North Carolina Community Hospitals.22nd April 2021
  Precision medicine in advanced non-small cell lung cancer (NSCLC) requires molecular biomarker testing in patients with non-squamous and select patients with squamous histologies, and PD-L1 testing in both.What are rates of molecular and PD-L1 biomarker testing in patients with advanced NSCLC in community practices and do rates vary by sociodemographic factors? What is the prevalence […]
• Evaluation of the diagnostic accuracy of bronchial brushing cytology in lung cancer: A meta-analysis.22nd April 2021
  Flexible bronchoscopy is commonly used to examine patients suspected to have lung cancer. Bronchial brushing is one of the cytological technologies for lung specimens obtained through a bronchoscope. However, the accuracy of bronchial brushing cytology (BBC) for lung cancer diagnosis is still inconclusive. The aim of this study was to evaluate the diagnostic accuracy of […]
• Utility of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients with Non-small Cell Lung Cancer.20th April 2021
  The utility of circulating tumor DNA (ctDNA) in detecting mutations and monitoring treatment response has not been well studied beyond a few actionable biomarkers in non-small cell lung cancer (NSCLC).How does the utility of circulating tumor DNA (ctDNA) compare to that of solid tumor biopsy in non-small cell lung cancer (NSCLC) patients?We retrospectively evaluated 370 […]
• Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer.19th April 2021
  Molecular testing is critical for identifying actionable variants in lung cancer for precision medicine. When tumor tissue samples are unavailable, archived cytological specimens (ACSs) can be used. The authors examined whether oncogenic variants could be accurately detected in ACSs versus paired formalin-fixed, paraffin-embedded (FFPE) tumor tissues with in vitro diagnostic tests.The authors collected 18 ACSs […]
• Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.19th April 2021
  We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non-small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov identifier: NCT02142738) is an open-label, randomized controlled trial of pembrolizumab compared with platinum-based chemotherapy in patients with previously untreated NSCLC with a programmed death ligand-1 (PD-L1) tumor proportion score of at least 50% and no […]
• Genetic polymorphism in ATIC is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer.16th April 2021
  Patients with advanced non-small-cell lung cancer who are treated with pemetrexed display a wide variation in clinical response and toxicity. In this prospective, multicentre cohort study, we investigated the association with treatment effectiveness and toxicity of 10 polymorphisms in nine candidate genes, covering the folate pathway (MTHFR), cell transport (SLC19A1/ABCC2/ABCC4), intracellular metabolism (FPGS/GGH) and target […]
• Lung cancer probability and clinical outcomes of baseline and new subsolid nodules detected on low-dose CT screening.16th April 2021
  Limited data are available regarding the management of subsolid nodules detected on lung cancer screening with low-dose CT (LDCT). We aimed to determine the characteristics of screen-detected subsolid nodules, and to evaluate the probability of lung cancer and the clinical course of subsolid nodules detected at baseline and during follow-up screening.We evaluated 50 132 asymptomatic adults […]
• Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study.4th April 2021
  Previous studies suggested that the prevalence of chronic respiratory disease in patients hospitalised with COVID-19 was lower than its prevalence in the general population. The aim of this study was to assess whether chronic lung disease or use of inhaled corticosteroids (ICS) affects the risk of contracting severe COVID-19.In this population cohort study, records from […]
• Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.29th March 2021
  Furmonertinib (AST2818) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting both sensitising EGFR and EGFR Thr790Met (T790M) mutations. This study aimed to assess the efficacy and safety of furmonertinib in patients with EGFR T790M mutated advanced non-small-cell lung cancer (NSCLC).This study was a single-arm, open-label, phase 2b study at 46 […]
• ONCOLYTIC VIRUS IN GLIOMAS: A REVIEW OF HUMAN CLINICAL INVESTIGATIONS.27th March 2021
  Gliomas remain one of the more frustrating targets for oncologic therapy. Glioma resistance to conventional therapeutics is a product of their immune-privileged milieu behind the blood-brain barrier, in addition to their suppressive effect on the immune response itself. Taking the lead from the growing success of immunotherapy for systemic cancers such as lung cancer and […]
• Modification of Pathological T Classification for Non-small Cell Lung Cancer with Visceral Pleural Invasion: Data from 1,055 Cases of Cancers 3 cm or Less.22nd March 2021
  Visceral pleural invasion (VPI) with PL1 or PL2 increases the T classification from T1 to T2 in non-small cell lung cancers (NSCLCs) 3 cm or less. We proposed a modified T classification based on VPI to guide adjuvant therapy.Is it reasonable to upstage PL1-positive cases from T1 to T2 for NSCLCs 3 cm or less?In […]
• Provision of Smoking Cessation Resources in the Context of in-person Shared Decision Making for Lung Cancer Screening.22nd March 2021
  Lung cancer screening (LCS) is effective at reducing mortality for high-risk smokers. Mortality benefits go beyond early cancer detection, as shared-decision making (SDM) may present a “teachable moment” to reinforce cessation and provide resources.How well is smoking cessation performed during LCS SDM encounters and what patient and provider characteristics associated with smoking cessation assistance?This is […]
• Small cell lung cancer: a slightly less orphan disease after immunotherapy.19th March 2021
  Small cell lung cancer (SCLC) is an aggressive malignancy accounting for 15% of all diagnosed cases of lung cancer. After more than 15 years without any clinically relevant therapeutic advances, extensive disease SCLC has become the second thoracic malignancy for which immune checkpoint inhibitors (ICIs) have shifted the treatment paradigm to improve overall survival. Today, […]
• Pleural recurrence after transthoracic needle lung biopsy in stage I lung cancer: a systematic review and individual patient-level meta-analysis.16th March 2021
  Conflicting results exist regarding whether preoperative transthoracic biopsy increases the risk of pleural recurrence in early lung cancer. We conducted a systematic, patient-level meta-analysis to evaluate the risk of pleural recurrence in stage I lung cancer after percutaneous transthoracic lung biopsy.A systematic search of OVID-MEDLINE, Embase and the Cochrane Database of Systematic Reviews was performed […]
• Role of extracellular vesicles in chronic lung disease.13th March 2021
  To explore the role of extracellular vesicles (EVs) in chronic lung diseases.EVs are emerging as mediators of intercellular communication and possible diagnostic markers of disease. EVs harbour cargo molecules including RNA, lipids and proteins that they transfer to recipient cells. EVs are intercellular communicators within the lung microenvironment. Due to their disease-specific cargoes, EVs have […]
• Next-generation sequencing facilitates differentiating between multiple primary lung cancer and intrapulmonary metastasis: a case series.12th March 2021
  In lung cancer management, differential diagnosis between multiple primary lung cancer (MPLC) and intrapulmonary metastasis (IMP) is a critical point that is of direct therapeutic and clinical importance. However, this process often suffers from absence of a gold standard, resulting in equivocal cases. Herein, we present a series of three cases, in which genomic alteration […]
• Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force.9th March 2021
  The US Preventive Services Task Force (USPSTF) is updating its 2013 lung cancer screening guidelines, which recommend annual screening for adults aged 55 through 80 years who have a smoking history of at least 30 pack-years and currently smoke or have quit within the past 15 years.To inform the USPSTF guidelines by estimating the benefits […]
• Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement.9th March 2021
  Lung cancer is the second most common cancer and the leading cause of cancer death in the US. In 2020, an estimated 228 820 persons were diagnosed with lung cancer, and 135 720 persons died of the disease. The most important risk factor for lung cancer is smoking. Increasing age is also a risk factor for lung […]
• Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.8th March 2021
  In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability. CheckMate 451, a double-blind phase III trial, evaluated nivolumab plus ipilimumab and nivolumab monotherapy as maintenance therapy following first-line chemotherapy for ED-SCLC.Patients with ED-SCLC, Eastern Cooperative Oncology Group performance status 0-1, and no progression after ≤ 4 […]
• Real-world outcomes of patients with advanced non-small cell lung cancer treated with anti-PD1 therapy on the basis of PD-L1 Results in EBUS-TBNA vs. histological specimens.6th March 2021
  PD-L1 testing is feasible in a majority of specimens acquired using endobronchial ultrasound-guided needle aspiration (EBUS-TBNA).Are the outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors (ICI) on the basis of PD-L1 expression in EBUS-TBNA samples significantly different from those of patients who are treated on the basis of PD-L1 expression in histological […]
• Risk Perception Among a Lung Cancer Screening Population.5th March 2021
  A successful lung cancer screening program requires a patient cohort at sufficient risk of developing cancer who are willing to participate. Among other factors, a patient’s lung cancer risk perception may inform their attitudes towards screening and smoking-cessation programs.This study analyzed data from the Pan-Canadian Early Detection of Lung Cancer (PanCan) Study to address the […]
• High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.4th March 2021
  Concurrent chemoradiotherapy is standard treatment for limited stage small-cell lung cancer (SCLC). Twice-daily thoracic radiotherapy of 45 Gy in 30 fractions is considered to be the most effective schedule. The aim of this study was to investigate whether high-dose, twice-daily thoracic radiotherapy of 60 Gy in 40 fractions improves survival.This open-label, randomised, phase 2 trial […]
• Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.1st March 2021
  Genetic rearrangements of the tyrosine receptor kinase ROS proto-oncogene 1 (ROS1) are oncogenic drivers in non-small-cell lung cancer (NSCLC). We report the results of an updated integrated analysis of three phase I or II clinical trials (ALKA-372-001, STARTRK-1, and STARTRK-2) of the ROS1 tyrosine kinase inhibitor, entrectinib, in ROS1 fusion-positive NSCLC.The efficacy-evaluable population included adults […]
• Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.27th February 2021
  Lorlatinib, a potent, brain-penetrant, third-generation ALK tyrosine kinase inhibitor (TKI), has substantial activity against ALK-positive non-small-cell lung cancer (NSCLC). This study assessed the overall, intracranial, and extracranial efficacy of lorlatinib in ALK-positive NSCLC that progressed on second-generation ALK TKIs.In the ongoing phase II study (NCT01970865), patients with ALK-positive advanced NSCLC treated with ≥1 prior second-generation […]
• European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer.24th February 2021
  We predicted cancer mortality statistics for 2021 for the European Union (EU) and its five most populous countries plus the UK. We also focused on pancreatic cancer and female lung cancer.We obtained cancer death certifications and population data from the World Health Organization and Eurostat databases for 1970-2015. We predicted numbers of deaths and age-standardized […]
• Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina.23rd February 2021
  Immune checkpoint inhibitors (ICI) are standard treatments for advanced non-small cell lung cancer and have expanded use in small cell lung cancer. While generally better tolerated than traditional chemotherapy, immune-related adverse events, such as immune checkpoint inhibitor-related pneumonitis (ICI-P), remain poorly understood toxicities that limit ICI treatment and can result in considerable morbidity. In this […]
• Access to lung cancer screening in the Veterans Health Administration: Does geographic distribution match need in the population?22nd February 2021
  Studies show uneven access to Medicare-approved lung cancer screening (LCS) programs across the US. The Veterans Health Administration (VA), the largest national US integrated health system, is potentially well-positioned to coordinate LCS services across regional units to ensure access matches distribution of need nationally.To what extent does LCS access (considering both VA and partner sites) […]
• Management of Dyspnea in Advanced Cancer: ASCO Guideline.22nd February 2021
  To provide guidance on the clinical management of dyspnea in adult patients with advanced cancer.ASCO convened an Expert Panel to review the evidence and formulate recommendations. An Agency for Healthcare Research and Quality (AHRQ) systematic review provided the evidence base for nonpharmacologic and pharmacologic interventions to alleviate dyspnea. The review included randomized controlled trials (RCTs) […]
• Comparing functional decline and distress from symptoms in people with thoracic life-limiting illnesses: lung cancers and non-malignant end-stage respiratory diseases.17th February 2021
  Malignant and non-malignant respiratory diseases account for >4.6 million deaths annually worldwide. Despite similar symptom burdens, serious inequities in access to palliative care persists for people with non-malignant respiratory diseases.To compare functional decline and symptom distress in advanced malignant and non-malignant lung diseases using consecutive, routinely collected, point-of-care national data.The Australian national Palliative Care Outcomes Collaboration […]
• Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.16th February 2021
  To provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC) with driver alterations. A guideline update for systemic therapy for patients with stage IV NSCLC without driver alterations was published separately.The American Society of Clinical Oncology and Ontario Health (Cancer Care Ontario) NSCLC Expert […]
• Shared Decision Making for Lung Cancer Screening: How Well are we “Sharing”?8th February 2021
  Lung cancer screening (LCS) reduces lung cancer mortality, but it also carries a range of risks. Shared decision making (SDM) is a process of engaging patients in their health care decisions and is a vital component of LCS.What is the quality of SDM among patients recently assessed for LCS?Cross-sectional study of screened patients recruited from […]
• Potential Disparities by Sex and Race-ethnicity in Lung Cancer Screening Eligibility Rates.5th February 2021
  Criteria for low-dose CT lung cancer screening vary across guidelines. Knowledge of the eligible pool across demographic groups can enable policy and programmatic decision-making, particularly for disproportionately affected populations.What are the eligibility rates for low-dose CT screening according to sex and race/ethnicity and how do these rates relate to corresponding lung cancer incidence rates?This was […]
• Proposed Quality Metrics for Lung Cancer Screening Programs: A National Lung Cancer Roundtable Project.4th February 2021
  Lung cancer screening with a low radiation dose chest CT scan is the standard of care for screen eligible individuals. The net benefit of screening may be optimized by delivering high-quality care, capable of maximizing the benefit and minimizing the harms of screening. Valid, feasible, and relevant indicators of the quality of lung cancer screening […]
• Chr15q25 genetic variant (rs16969968) independently confers risk of lung cancer, COPD and smoking intensity in a prospective study of high-risk smokers.9th January 2021
  While cholinergic receptor nicotinic alpha 5 (CHRNA5) variants have been linked to lung cancer, chronic obstructive pulmonary disease (COPD) and smoking addiction in case-controls studies, their corelationship is not well understood and requires retesting in a cohort study.To re-examine the association between the CHRNA5 variant (rs16969968 AA genotype) and the development of lung cancer, relative […]
• Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants.6th January 2021
  Two cases of pediatric lung cancer (in 23-month-old and 6-year-old boys) resulting from mother-to-infant transmission of uterine cervical tumors were incidentally detected during routine next-generation sequencing of paired samples of tumor and normal tissue. Spontaneous regression of some lesions in the first child and slow growth of the tumor mass in the second child suggested […]
• Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants.6th January 2021
  Two cases of pediatric lung cancer (in 23-month-old and 6-year-old boys) resulting from mother-to-infant transmission of uterine cervical tumors were incidentally detected during routine next-generation sequencing of paired samples of tumor and normal tissue. Spontaneous regression of some lesions in the first child and slow growth of the tumor mass in the second child suggested […]
• A Comparison of the PanCan Model and Lung-RADS to Assess Cancer Probability Among People With Screening-Detected, Solid Lung Nodules.4th January 2021
  The Pan-Canadian Early Detection of Lung Cancer (PanCan) risk model and the Lung CT Screening Reporting & Data System (Lung-RADS) estimate cancer probability for screening-detected nodules. The accuracy and agreement of these models require further study.What is the performance of the PanCan model and Lung-RADS to estimate the probability of cancer in screening-detected solid nodules?We […]
• Is Biopsy of Contralateral Hilar N3 Lymph Nodes With Negative PET-CT Scan Findings Necessary When Performing Endobronchial Ultrasound Staging?4th January 2021
  Systematic endobronchial ultrasound (EBUS)-guided lung cancer staging starts with hilar N3 nodes, proceeding sequentially to mediastinal N3, N2, and N1 nodes, with sampling of all enlarged nodes (size, ≥ 5 mm) by EBUS. However, procedure time is limited by patient comfort when moderate sedation is used. It is unclear if EBUS staging should start with hilar N3 […]
• Tumor mutational burden on cytological samples: A pilot study.30th December 2020
  Immune-checkpoint inhibitors (ICIs) represent an important treatment option for patients who have advanced stage non-small cell lung cancer (NSCLC). Currently, evaluation of the expression level of programmed death-ligand 1 (PD-L1) has proven highly successful as a positive predictive biomarker for ICIs. In addition to PD-L1, other promising predictive biomarkers are emerging, including high tumor mutational […]
• Cardiac Safety of Osimertinib: A Review of Data.28th December 2020
  Osimertinib is a third-generation, CNS-active, irreversible, oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that potently and selectively inhibits both EGFR-TKI-sensitizing and T790M resistance mutations. We assess the cardiac failure risk in patients receiving osimertinib by evaluating the available data.Post hoc analyses of cardiac data from (1) studies in patients with advanced non-small-cell lung […]
• Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage?22nd December 2020
  The eighth edition of nodal classification for non-small cell lung cancer (NSCLC) is defined only by the anatomical location of metastatic lymph nodes.We sought to evaluate the prognostic significance and discriminatory capability of the number of involved nodal stations (nS) in a large Chinese cohort.A total of 4,011 NSCLC patients undergoing surgical resection between 2009 […]
• Association of First Primary Cancer With Risk of Subsequent Primary Cancer Among Survivors of Adult-Onset Cancers in the United States.22nd December 2020
  The number of cancer survivors who develop new cancers is projected to increase, but comprehensive data on the risk of subsequent primary cancers (SPCs) among survivors of adult-onset cancers are limited.To quantify the overall and cancer type-specific risks of SPCs among adult-onset cancer survivors by first primary cancer (FPC) types and sex.A retrospective cohort study […]
• Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.21st December 2020
  Immunotherapy combined with chemotherapy has been shown to be efficacious as treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) without targetable genetic aberrations; however, there is scarce evidence of the effectiveness of the combinations in the Asian population. We evaluated camrelizumab plus chemotherapy against non-squamous NSCLC in China.We did a randomised, open-label, multicentre, phase 3 […]
• Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma.18th December 2020
  Despite the clinical importance of assessing smoking history and advising patients who smoke to quit, lung cancer patients often experience feelings of blame and stigma during clinical encounters with their oncology care providers (OCPs). Promoting empathic communication during these encounters may help reduce patients’ experience of stigma and improve related clinical outcomes. This paper presents […]
• Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma.18th December 2020
  Despite the clinical importance of assessing smoking history and advising patients who smoke to quit, lung cancer patients often experience feelings of blame and stigma during clinical encounters with their oncology care providers (OCPs). Promoting empathic communication during these encounters may help reduce patients’ experience of stigma and improve related clinical outcomes. This paper presents […]
• Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.17th December 2020
  ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor (EGFR) mutation-positive resected stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC). Here, we report the final overall survival (OS) results.From September 2011 to April 2014, […]
• Variation in oral microbiome is associated with future risk of lung cancer among never-smokers.15th December 2020
  To prospectively investigate whether diversity in oral microbiota is associated with risk of lung cancer among never-smokers.A nested case-control study within two prospective cohort studies, the Shanghai Women’s Health Study (n=74 941) and the Shanghai Men’s Health Study (n=61 480).Lifetime never-smokers who had no cancer at baseline. Cases were subjects who were diagnosed with incident […]
• Validation of the BRODERS classifier (Benign versus aggressive nODule Evaluation using Radiomic Stratification), a novel high-resolution computed tomography-based radiomic classifier for indeterminate pulmonary nodules.11th December 2020
  Implementation of low-dose chest computed tomography (CT) lung cancer screening and the ever-increasing use of cross-sectional imaging are resulting in the identification of many screen- and incidentally detected indeterminate pulmonary nodules. While the management of nodules with low or high pretest probability of malignancy is relatively straightforward, those with intermediate pretest probability commonly require advanced […]
• Quality of dying and death in patients with interstitial lung disease compared with lung cancer: an observational study.10th December 2020
  There is limited knowledge regarding the quality of dying and death (QODD) and end-of-life interventions in patients with interstitial lung disease (ILD). Hence, differences in QODD and end-of-life interventions between patients with ILD and those with lung cancer (LC) remain poorly understood.The primary aim of this study was to explore the differences in QODD and […]
• Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.7th December 2020
  First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum-etoposide) showed a significant improvement in overall survival versus platinum-etoposide alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) in the CASPIAN study. Here we report updated results, including the primary analysis for overall survival with durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide alone.CASPIAN is an […]
• Performance of Risk factor-based Guidelines and Model-based Chest CT Lung Cancer Screening in World Trade Center Exposed Fire Department Rescue/Recovery Workers.6th December 2020
  Lung cancer is a leading cause of cancer incidence and death in the US. Risk factor-based guidelines and risk model-based strategies are used to identify patients who could benefit from LDCT screening. Few studies compare guidelines/models within the same cohort. We evaluate lung cancer screening performance of two risk factor-based guidelines (US Preventive Services Task […]
• Safety and Efficacy of Quavonlimab, a Novel Anti-CTLA-4 Antibody (MK-1308), in Combination with Pembrolizumab in First-Line Advanced Non-Small Cell Lung Cancer.4th December 2020
  Quavonlimab (MK-1308), a novel anti-CTLA-4 antibody, in combination with pembrolizumab was investigated in a phase I study.Dose-escalation phase (DE): patients with advanced/metastatic solid tumors received an initial flat dose of quavonlimab as monotherapy (25 mg [cohort 1], 75 mg [cohort 2], or 200 mg [cohort 3]) followed by 4 treatments of the same quavonlimab dose […]
• Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients with Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.20th November 2020
  The main goal of management in patients with NSCLC and MPE is palliation. PVatients with MPE and actionable mutations, because their disease is expected to quickly and markedly respond to targeted therapy, are less likely than those without actionable mutations to receive definitive MPE management. Whether such management is indicated in these patients is unclear.The […]
• Sex and survival after surgery for lung cancer: A Swedish nationwide cohort.20th November 2020
  Prior reports on a possible female survival advantage in both surgical and non-surgical cohorts of patients with lung cancer are conflicting. Previously reported differences in survival following lung cancer surgery could be due to insufficient control for disparities in risk factor profile in men and women.Do women who undergo pulmonary resections for lung cancer have […]
• First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.18th November 2020
  Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-positive non-small-cell lung cancer (NSCLC). The efficacy of lorlatinib, as compared with that of crizotinib, as first-line treatment for advanced ALK-positive NSCLC is unclear.We conducted a global, randomized, phase 3 trial comparing lorlatinib with crizotinib in 296 patients […]
• Institution-level differences in quality and outcomes of lung cancer resections in the United States.16th November 2020
  Institution-level disparities in non-small cell lung cancer (NSCLC) survival may be driven by reversible differences in care-delivery processes. We quantified the impact of differences in readily identifiable quality metrics on long-term survival disparities in resected NSCLC.how do reversible differences in oncologic quality of care contribute to institution-level disparities in early-stage NSCLC survival?We retrospectively analyzed patients […]
• Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.8th November 2020
  Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating advanced RET-altered thyroid cancers and non-small cell lung cancer (NSCLC). It is critical to analyze RET mutants resistant to these drugs and unravel the molecular basis to improve patient outcomes.Cell-free DNAs (cfDNAs) were analyzed in a RET-mutant medullary thyroid […]
• Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.1st November 2020
  CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid […]